This course is designed to provide clinicians in practice and trainees with a comprehensive review and update of the clinical practice parameters across most sub-disciplines of radiation oncology, including sarcomas and the use of radiation therapy for palliative purposes. The course will review key evidence that forms the basis for current clinical practice guidelines and trends in new approaches. Additionally, the course will cover oligometastatic disease and MRI-guided radiation therapy.
The activity is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, nurses and all other health professionals involved in the field of radiation oncology.
Upon completion of this live activity, attendees should be able to do the following:
1. Describe the underlying rationale for locally ablative therapy in oligometastatic disease.
2. Describe the challenges in defining oligometastatic and oligoprogressive disease.
3. Apply recent clinical evidence in the management of patients with oligometastatic disease.
Brian Kavanagh, MD, MPH, FASTRO, is employed by University of Colorado and has no other disclosures to declare.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 0.50 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 0.50 Certificate of AttendanceThis activity was designated for 0.50 AMA PRA Category 1 Credit™.